JP3590274B2 - Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient - Google Patents
Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient Download PDFInfo
- Publication number
- JP3590274B2 JP3590274B2 JP25852698A JP25852698A JP3590274B2 JP 3590274 B2 JP3590274 B2 JP 3590274B2 JP 25852698 A JP25852698 A JP 25852698A JP 25852698 A JP25852698 A JP 25852698A JP 3590274 B2 JP3590274 B2 JP 3590274B2
- Authority
- JP
- Japan
- Prior art keywords
- sedative
- active ingredient
- trimethoxybenzene
- present
- fragrance composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001624 sedative effect Effects 0.000 title claims description 37
- 239000000932 sedative agent Substances 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title claims description 23
- 230000008016 vaporization Effects 0.000 title claims description 9
- 239000004480 active ingredient Substances 0.000 title claims description 8
- 239000003205 fragrance Substances 0.000 title description 21
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical group COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 claims description 20
- CRUILBNAQILVHZ-UHFFFAOYSA-N 1,2,3-trimethoxybenzene Chemical group COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002304 perfume Substances 0.000 claims description 7
- 238000009834 vaporization Methods 0.000 claims description 6
- 229940030010 trimethoxybenzene Drugs 0.000 claims description 5
- RIZBLVRXRWHLFA-UHFFFAOYSA-N 3,5-dimethoxytoluene Chemical compound COC1=CC(C)=CC(OC)=C1 RIZBLVRXRWHLFA-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002781 deodorant agent Substances 0.000 description 6
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 239000013040 bath agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- -1 colon Substances 0.000 description 3
- 239000003915 liquefied petroleum gas Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- AGIQIOSHSMJYJP-UHFFFAOYSA-N 1,2,4-Trimethoxybenzene Chemical compound COC1=CC=C(OC)C(OC)=C1 AGIQIOSHSMJYJP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N phenethyl acetate Chemical compound CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000010666 rose oil Substances 0.000 description 2
- 235000019719 rose oil Nutrition 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- YIXWTOHVYXPCMF-UHFFFAOYSA-N 1,2,3-triethoxybenzene Chemical compound CCOC1=CC=CC(OCC)=C1OCC YIXWTOHVYXPCMF-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- QUMXDOLUJCHOAY-UHFFFAOYSA-N alpha-methylbenzyl acetate Natural products CC(=O)OC(C)C1=CC=CC=C1 QUMXDOLUJCHOAY-UHFFFAOYSA-N 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 description 1
- UFLHIIWVXFIJGU-UHFFFAOYSA-N hex-3-en-1-ol Natural products CCC=CCCO UFLHIIWVXFIJGU-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は鎮静剤及び鎮静香料組成物、特に気化した有効成分を吸引することにより鎮静作用を得られる鎮静剤に関する。
【０００２】
【従来の技術】
現代社会におけるストレスは不眠症等の各種生理的、心理的態様で発現するが、一方でこれらの発現は必ずしも病的な状態に至るとは限らず、一般的な経口投与、或いは注射投与等、医師の監督下を前提とする鎮静剤などの使用には限界があった。
【０００３】
従来アロマセラピーにおいてラベンダーやカモミルなどに鎮静効果があることが伝承的に確認されており、これらは香りにより鎮静効果を発揮できるため、人体に対する投与に際して新たなストレスを付加することがないという利点を有する。しかしながら、これらの香り自体に個人的な好き嫌いがあり、必ずしも汎用できるものではなかった。
【０００４】
これに対し、例えば特開平６−１７２７８１には、１，３−ジメトキシ−５−メチルベンゼンに鎮静効果があり、しかもこれを香料などに添加して気化吸引させることによっても効果が発現し、さらに１，３−ジメトキシ−５−メチルベンゼン自体の香りは強くないため、各種香料に添加して用い得ることが報告されている。
【０００５】
【発明が解決しようとする課題】
しかしながら、各種香料などに添加し、しかもその基調とする香気を変更しないためには、より他種にわたる気化吸引用鎮静剤の開発が要望される。
すなわち、前記１，３−ジメトキシ−５−メチルベンゼンは一般にグリーンノート系の香りを有し、強い香りは有しないため各種香料に添加可能ではあるが、香料によっては相性が良好でないものもある。
本発明は前記従来技術の課題に鑑みなされたものであり、その目的は各種の香りに対して適合性のある気化吸引用鎮静剤を提供することにある。
【０００６】
【課題を解決するための手段】
前記目的を達成するために本発明者らが鋭意検討を行った結果、フェノリックな甘さとスパイシー・ウッディーな香りを有するトリアルコキシベンゼンに優れた鎮静効果があることを見出し、本発明を完成するに至った。
すなわち本発明にかかる気化吸引用鎮静剤は、トリアルコキシベンゼンを有効成分とすることを特徴とする。
【０００７】
また、本発明において、トリアルコキシベンゼンはトリメトキシベンゼンであることが好適である。
また、本発明において、トリメトキシベンゼンは１，３，５−トリメトキシベンゼンであることが好適である。
【０００８】
本発明にかかる鎮静香料組成物は、前記気化吸引用鎮静剤を有効成分とし、トリアルコキシベンゼンの組成物中における存在量は、０．５重量％以上、５０重量％以下であることを特徴とする。
また、本発明において、組成物中におけるトリアルコキシベンゼンの存在量は１．０重量％以上、２０重量％以下であることが好適である。
【０００９】
【発明の実施の形態】
以下、本発明の構成をさらに詳細に説明する。
本発明において特徴的なトリアルコキシベンゼンは、下記一般式１で表される。
【化１】
このうち、Ｒ１，Ｒ２，Ｒ３は、好ましくはＣＨ３又はＣ２Ｈ５である。
【００１０】
そして、Ｒ１，Ｒ２，Ｒ３のすべてがメチル基のときのトリメトキシベンゼン、Ｒ１，Ｒ２，Ｒ３のすべてがエチル基のときのトリエトキシベンゼンなどがその例として挙げられる。これらの中で１，２，３−トリメトキシベンゼン、１，２，４−トリメトキシベンゼン、１，３，５−トリメトキシベンゼンは市販されており、これらを購入し液体クロマトグラフィーを用いて分取後、蒸留精製して用いることができる。その他のトリアルコキシベンゼンは市販のフェノール誘導体を購入し、定法によりアルキル化を行い、精製後用いることができる。トリアルコキシベンゼンの中では１，３，５−トリメトキシベンゼンが最も好ましく、またこれらの位置異性体による効果の差は僅かである。
【００１１】
これらのトリアルコキシベンゼンの香気はフェノリックな甘さとスパイシー・ウッディーな香りを有している。
また、本発明の鎮静香料組成物は、前記有効成分であるトリアルコキシベンゼンとともに、必要に応じて補助成分と組み合わせて香水、コロン、シャンプー・リンス類、スキンケア用品、ボディーシャンプー、ボディーリンス、ボディーパウダー類、芳香剤、消臭剤、浴剤などに用いられる。
【００１２】
香料組成物中におけるトリアルコキシベンゼンの含有量は使用目的などを考慮して適宜決定すればよいが、通常は０．５〜５０％、好ましくは１〜２０％が適当である。含有量が０．５％以上において有効な鎮静効果を発現することができ、また５０重量％を越える量を含有させても鎮静効果としては特に顕著な効果の向上が認められず、他の香料とのバランスを考慮するとこれ以上加えることは好ましくない。
【００１３】
以下、本発明の実施態様をさらに詳細に説明する。
まず、本発明で採用した試験方法について説明する。
随伴性陰性変動（Ｃｏｎｔｉｇｅｎｔ Ｎｅｇａｔｉｖｅ Ｖａｒｉａｔｉｏｎ 以下、ＣＮＶ）と呼ばれる陰性の電位の変化を測定した。ＣＮＶは注意、期待、予期などの心的過程、また意識レベルの変動と関連する脳の緩徐な電位変動である。
【００１４】
目的とする化合物を検索するための実験では、警告刺激音から２秒後に運動の開始を意味する光信号が続き、光を認識すると同時にボタン押しの運動反応が要求される。この一連の繰り返しの中で、香りの試料は鼻先約１０ｃｍ先に設置されており、呼吸に伴い常に香りを認知することができる。ＣＮＶ測定のための電極は前頭部に装着され、耳朶との間の電位記録が測定される。覚醒効果を示すカフェインを投与した場合、ＣＮＶの振幅が増大し、鎮静効果を示すニトロゼパムを投与した場合にはＣＮＶの振幅は減少することが報告されている。
【００１５】
これらの変動は音刺激後４００〜１０００ｍｓｅｃの初期成分に顕著に現れる。この区間の変動面積をブランク（無臭刺激）を１００％として比較した百分率（％）で表す。なお、香りはラテン方格に従って提示している。
１００％以上の場合は覚醒効果が、１００％以下の場合には鎮静効果があることを表している。多くの天然精油について随伴性変動を用いて精査した結果、精油に鎮静効果と覚醒効果を有するものがあることが判っている。
【００１６】
本発明の効果確認
１，３−ジメトキシ−５−メチルベンゼン（ＤＭＭＢ）と、本発明にかかる１，３，５−トリメトキシベンゼン（ＴＭＢ）、その他天然精油であるレモンオイル、ローズオイルをそれぞれ５％エタノール溶液とし、前記ＣＮＶに対する影響を測定した。すなわち、健康な成人女性５名を被験者として前記方法により試験を行った。結果を図１に示す。同図より明らかなように、レモンオイルには伝承通りの覚醒効果が確認され、ローズオイルには覚醒、鎮静のいずれも確認されない。しかし、１，３，５−トリメトキシベンゼンに代表されるトリアルコキシベンゼンには、１，３−ジメトキシ−５−メチルベンゼンと比較しても良好な鎮静効果を示していることが確認された。
【００１７】
【実施例】
以下、本発明にかかる鎮静香料組成物の好適な実施例を説明する。なお、本発明は、これらに限定されるものではない。
【００１８】
実施例１：フローラル調鎮静香料組成物
ｎ−ノナナール１０％ ０．１重量部
ベンジルベンゾエート １．０
シトロネロール １０．０
シトロネリールアセテート ０．２
シトロネリールフォメート ０．１
オイゲノール ０．５
ゲラニオール １２．５
ゲラニールアセテート ０．３
シス−３−ヘキセノール ０．２
ネロール ２．５
フェニルエチルアルコール ７０．０
フェニルエチルアセテート １．５
１，３，５−トリメトキシベンゼン ５．０
【００１９】
実施例３：浴剤
炭酸水素ナトリウム ７０重量部
無水硫酸ナトリウム ２８．８
実施例２の鎮静香料組成物 １
色素Ｙ−２０２−１ ０．２
香料を除いた成分をＶ型ミキサーにて均一になるまで攪拌した後、鎮静香料組成物を加え、さらに均一になるまで充分に攪拌して浴剤を得た。
【００２１】
実施例４：ゲル芳香剤
カラギーナン ３．０重量部
プロピレングリコール ２．０
プロピルパラベン ０．３
実施例２の鎮静香料組成物 ５．０
水 ８９．７
カラギーナン、プロピレングリコール及びプロピルパラベンを混合して攪拌しながら水を加え、これを穏やかに攪拌しながら約８０℃になるまで加熱した。その後、約６５℃とし、これをホモジナイザーを用いて３０００ｒｐｍで攪拌しながら鎮静香料組成物を加えて均一な相とした後、所定の容器に流し込み、自然冷却して芳香剤を得た。
【００２２】
実施例５：リキッドタイプ芳香剤
９５％エタノール ２５．０重量部
界面活性剤 ５．０
実施例３の鎮静香料組成物 ３．０
水 ６７．０
水を除く各成分を混合し、穏やかに攪拌しながら水を加え、均一にして芳香剤を得た。なお、界面活性剤としてポリオキシエチレンノニルフェニルエーテルＥＯ−１３を用いた。
【００２３】
実施例６：リキッドタイプ消臭剤
消臭原液ＦＳ−５００Ｍ（白井松新薬株式会社製） ５．０重量部
９５％エタノール １０．０
界面活性剤 １０．０
５％１，３，５−トリメトキシベンゼン １０．０
（エタノール溶液）
水 ６５．０
水井外の各成分を混合し、穏やかに攪拌しながら水を加えて消臭剤（リキッドタイプ）を得た。なお、界面活性剤としてポリオキシエチレンノニルフェニルエーテルＥＯ−１０を用いた。
【００２４】
実施例７：エアゾールタイプ
消臭原液ＦＳ−５００Ｍ ５．０重量部
９５％エタノール ２０．０
１％１，３，５−トリメトキシベンゼン １０．０
（エタノール溶液）
水 ４０．０
液化石油ガス（４．０ｋｇ／ｃｍ２ ２０℃） ２５．０
液化石油ガス以外の成分を混合、攪拌して均一とし、所定の量をエアゾール容器に入れてバルブを取り付けた後、液化石油ガスを注入して消臭剤（エアゾールタイプ）を得た。
【００２５】
【発明の効果】
以上説明したように本発明にかかる鎮静剤及びそれを配合した鎮静香料組成物によれば、トリアルコキシベンゼンを有効成分とするので、従来知られている１，３−ジメトキシ５−メチルベンゼンとは異なる香りを有し、しかもそれらを気化、吸引させるのみで鎮静効果が得られ、使用者に身体的、心理的負担をかけるおそれがない。
【図面の簡単な説明】
【図１】本発明にかかる１，３，５−トリメトキシベンゼンと、他の比較例についてのＣＮＶ測定結果を示す説明図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a sedative and a sedative fragrance composition, and more particularly to a sedative capable of obtaining a sedative effect by inhaling a vaporized active ingredient.
[0002]
[Prior art]
Stress in modern society is expressed in various physiological and psychological aspects such as insomnia, but these expressions do not always lead to pathological conditions, such as general oral administration or injection administration, The use of sedatives, etc. under the supervision of a doctor was limited.
[0003]
Conventionally, it has been traditionally confirmed that lavender and chamomil have a sedative effect in aromatherapy, and since they can exert a sedative effect by fragrance, there is an advantage that new stress is not added when administered to the human body. Have. However, these scents themselves have personal likes and dislikes, and are not always versatile.
[0004]
On the other hand, for example, in JP-A-6-172781, 1,3-dimethoxy-5-methylbenzene has a sedative effect, and the effect is exhibited by adding this to a fragrance or the like and vaporizing and sucking it. It has been reported that 1,3-dimethoxy-5-methylbenzene itself is not strong and can be used by adding it to various fragrances.
[0005]
[Problems to be solved by the invention]
However, in order to add to various fragrances and the like, and not to change the base fragrance, there is a demand for the development of other types of sedatives for vaporization and suction.
That is, the 1,3-dimethoxy-5-methylbenzene generally has a green note scent and does not have a strong scent, so that it can be added to various fragrances. However, some fragrances have poor compatibility.
SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned problems of the related art, and an object of the present invention is to provide a sedative for vaporization and suction that is compatible with various scents.
[0006]
[Means for Solving the Problems]
As a result of intensive studies by the present inventors to achieve the above object, it was found that trialkoxybenzene having a phenolic sweetness and a spicy woody aroma has an excellent sedative effect, and to complete the present invention. Reached.
That is, the sedative for vaporization and suction according to the present invention is characterized by using trialkoxybenzene as an active ingredient.
[0007]
In the present invention, the trialkoxybenzene is preferably trimethoxybenzene.
In the present invention, the trimethoxybenzene is preferably 1,3,5-trimethoxybenzene.
[0008]
The sedative fragrance composition according to the present invention comprises the sedative for vaporization and inhalation as an active ingredient, and the amount of trialkoxybenzene in the composition is 0.5% by weight or more and 50% by weight or less. I do.
In the present invention, the amount of trialkoxybenzene in the composition is preferably 1.0% by weight or more and 20% by weight or less.
[0009]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the configuration of the present invention will be described in more detail.
The trialkoxybenzene characteristic of the present invention is represented by the following general formula 1.
Embedded image
Among them, R 1 , R 2 , and R 3 are preferably CH 3 or C 2 H 5 .
[0010]
Examples thereof include trimethoxybenzene when all of R 1 , R 2 and R 3 are methyl groups, and triethoxybenzene when all of R 1 , R 2 and R 3 are ethyl groups. Among these, 1,2,3-trimethoxybenzene, 1,2,4-trimethoxybenzene, and 1,3,5-trimethoxybenzene are commercially available, and these are purchased and analyzed by liquid chromatography. After collection, it can be purified by distillation and used. Other trialkoxybenzenes can be used after purchasing a commercially available phenol derivative, performing alkylation by a conventional method, and purifying it. Among the trialkoxybenzenes, 1,3,5-trimethoxybenzene is most preferred, and the difference in the effects of these positional isomers is slight.
[0011]
The aroma of these trialkoxybenzenes has a phenolic sweetness and a spicy woody aroma.
In addition, the sedative fragrance composition of the present invention may be used in combination with the above-mentioned trialkoxybenzene as an active ingredient, if necessary, in combination with an auxiliary ingredient, perfume, colon, shampoo / rinse, skin care product, body shampoo, body rinse, body powder. Used for foods, fragrances, deodorants, bath agents, etc.
[0012]
The content of trialkoxybenzene in the fragrance composition may be appropriately determined in consideration of the purpose of use and the like, but is usually 0.5 to 50%, preferably 1 to 20%. When the content is 0.5% or more, an effective sedative effect can be exhibited. Even when the content exceeds 50% by weight, no remarkable improvement in the sedative effect is observed. Considering the balance with the above, it is not preferable to add more.
[0013]
Hereinafter, embodiments of the present invention will be described in more detail.
First, the test method employed in the present invention will be described.
A change in a negative potential called a contingent negative variation (hereinafter, CNV) was measured. CNV is a gradual change in potential of the brain associated with mental processes such as attention, expectation, and expectation, as well as changes in the level of consciousness.
[0014]
In an experiment for searching for a compound of interest, a light signal indicating the start of exercise follows two seconds after the warning stimulus sound, and a motor reaction of button press is required at the same time as recognizing the light. In this series of repetitions, the scent sample is placed about 10 cm in front of the nose, and the scent can always be recognized with breathing. An electrode for CNV measurement is attached to the forehead, and a potential record with the earlobe is measured. It has been reported that the amplitude of CNV increases when caffeine showing an arousal effect is administered, and the amplitude of CNV decreases when nitrazepam showing a sedative effect is administered.
[0015]
These fluctuations appear remarkably in the initial component of 400 to 1000 msec after the sound stimulation. The variation area of this section is expressed as a percentage (%) in comparison with a blank (odorless stimulus) being 100%. The scent is presented according to the Latin square.
When it is 100% or more, it indicates that there is an arousal effect, and when it is 100% or less, it has a sedative effect. Scrutiny of many natural essential oils using contingency fluctuations has revealed that some of the essential oils have a sedative effect and a wakefulness effect.
[0016]
Confirmation of the effect of the present invention 1,3-dimethoxy-5-methylbenzene (DMMB), 1,3,5-trimethoxybenzene (TMB) according to the present invention, and other natural essential oils such as lemon oil and rose oil were 5 parts each. % Ethanol solution, and the effect on CNV was measured. That is, the test was performed by the above method using five healthy adult women as subjects. The results are shown in FIG. As is clear from the figure, the awakening effect according to the tradition was confirmed in lemon oil, and neither awakening nor sedation was observed in rose oil. However, it was confirmed that trialkoxybenzene represented by 1,3,5-trimethoxybenzene exhibited a favorable sedative effect as compared with 1,3-dimethoxy-5-methylbenzene.
[0017]
【Example】
Hereinafter, preferred examples of the sedative fragrance composition according to the present invention will be described. Note that the present invention is not limited to these.
[0018]
Example 1: Floral sedative perfume composition n-
Citronellol 10.0
Citronellyl acetate 0.2
Citronell reel formate 0.1
Eugenol 0.5
Geraniol 12.5
Geranyl acetate 0.3
Cis-3-hexenol 0.2
Nerol 2.5
Phenylethyl alcohol 70.0
Phenylethyl acetate 1.5
1,3,5-trimethoxybenzene 5.0
[0019]
Example 3: Bath agent Sodium bicarbonate 70 parts by weight anhydrous sodium sulfate 28.8
Sedative perfume composition of Example 2 1
Dye Y-202-1 0.2
After the components excluding the fragrance were stirred with a V-type mixer until the mixture became uniform, the soothing fragrance composition was added, and the mixture was sufficiently stirred until the mixture became uniform to obtain a bath agent.
[0021]
Example 4: Gel fragrance Carrageenan 3.0 parts by weight propylene glycol 2.0
Propyl paraben 0.3
Sedative perfume composition of Example 2 5.0
89.7 water
Carrageenan, propylene glycol and propylparaben were mixed and water was added with stirring and heated to about 80 ° C. with gentle stirring. Thereafter, the temperature was lowered to about 65 ° C., and the resulting mixture was stirred with a homogenizer at 3000 rpm to add a sedative fragrance composition to form a uniform phase. The mixture was poured into a predetermined container and naturally cooled to obtain an aromatic substance.
[0022]
Example 5: Liquid type fragrance 95% ethanol 25.0 parts by weight surfactant 5.0
Sedative perfume composition of Example 3 3.0
Water 67.0
The components except for water were mixed, and water was added with gentle stirring to obtain a uniform fragrance. In addition, polyoxyethylene nonyl phenyl ether EO-13 was used as a surfactant.
[0023]
Example 6: Liquid type deodorant Deodorant stock solution FS-500M (manufactured by Shirai Matsushin Pharmaceutical Co., Ltd.) 5.0 parts by weight 95% ethanol 10.0
Surfactant 10.0
5% 1,3,5-trimethoxybenzene 10.0
(Ethanol solution)
Water 65.0
The components outside the well were mixed, and water was added with gentle stirring to obtain a deodorant (liquid type). In addition, polyoxyethylene nonyl phenyl ether EO-10 was used as a surfactant.
[0024]
Example 7: Aerosol type Deodorant stock solution FS-500M 5.0 parts by weight 95% ethanol 20.0
1% 1,3,5-trimethoxybenzene 10.0
(Ethanol solution)
Water 40.0
Liquefied petroleum gas (4.0 kg / cm2 at 20 ° C) 25.0
Components other than the liquefied petroleum gas were mixed and stirred to make uniform, a predetermined amount was put in an aerosol container, a valve was attached, and then liquefied petroleum gas was injected to obtain a deodorant (aerosol type).
[0025]
【The invention's effect】
As described above, according to the sedative according to the present invention and the sedative fragrance composition containing the same, trialkoxybenzene is used as an active ingredient, so that conventionally known 1,3-dimethoxy-5-methylbenzene is It has different scents, and a sedative effect can be obtained only by vaporizing and inhaling them, and there is no risk of imposing a physical or psychological burden on the user.
[Brief description of the drawings]
FIG. 1 is an explanatory diagram showing CNV measurement results of 1,3,5-trimethoxybenzene according to the present invention and other comparative examples.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25852698A JP3590274B2 (en) | 1998-09-11 | 1998-09-11 | Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25852698A JP3590274B2 (en) | 1998-09-11 | 1998-09-11 | Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000086478A JP2000086478A (en) | 2000-03-28 |
| JP3590274B2 true JP3590274B2 (en) | 2004-11-17 |
Family
ID=17321446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25852698A Expired - Lifetime JP3590274B2 (en) | 1998-09-11 | 1998-09-11 | Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3590274B2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3519747B2 (en) * | 1992-09-25 | 2004-04-19 | 高砂香料工業株式会社 | Fragrance modifier that gives a soothing effect |
| WO2005000286A1 (en) * | 2003-06-27 | 2005-01-06 | Soiken Inc. | Composition for relieving or lessening fatigue and medical device fitted with the composition |
| FR2873920B1 (en) | 2004-08-06 | 2006-11-24 | Tagasako Internat Corp | USE OF TRIMETHOXYBENZENE AS A SEDATIVE IN FRAGRANCE COMPOSITIONS |
| FR2874009B1 (en) * | 2004-08-06 | 2006-12-01 | Tagasako Internat Corp | USE OF ALCOXYBENZENES AS BLOOD STIMULATING AGENT |
| FR2874024B1 (en) * | 2004-08-06 | 2007-10-12 | Tagasako Internat Corp | USE OF ALCOXYBENZENES AS AN ODORIFERANT AGENT FOR HOUSEHOLD PRODUCTS, INCLUDING INTERNAL DEODORIZERS |
| JP4648040B2 (en) * | 2005-03-08 | 2011-03-09 | 株式会社資生堂 | Generation method of air for improving biological function |
| JP4754860B2 (en) * | 2005-04-13 | 2011-08-24 | 株式会社 資生堂 | Sedative effect imparting agent for vaporization suction and sedative composition for vaporization suction containing the same |
| JP2010143884A (en) * | 2008-12-22 | 2010-07-01 | Shiseido Co Ltd | Chapped skin improving agent |
| JP2013006791A (en) * | 2011-06-24 | 2013-01-10 | Shiseido Co Ltd | Sedative for vaporization and inhalation, and sedative-flavoring composition containing the same |
| JP6065206B2 (en) * | 2012-12-13 | 2017-01-25 | 花王株式会社 | Fragrance composition |
-
1998
- 1998-09-11 JP JP25852698A patent/JP3590274B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000086478A (en) | 2000-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1941870B1 (en) | Perfume Composition comprising perilla aldehyde | |
| JP3519747B2 (en) | Fragrance modifier that gives a soothing effect | |
| JP2003119490A (en) | Psychosedative perfume composition | |
| JP3590274B2 (en) | Sedative for vaporizing inhalation and sedative fragrance composition containing the same as an active ingredient | |
| JPH0523245B2 (en) | ||
| JP5053472B2 (en) | Fragrance composition | |
| US20230200435A1 (en) | Caryophyllene-containing agent or composition and various applications thereof | |
| JPS63199292A (en) | Perfume composition and cosmetics containing the same | |
| KR102055499B1 (en) | Perfume composition for decreasing relative theta wave and relative alpha wave of brainwave containing essential oil of Chrysanthemum indicum L and use thereof | |
| JPH01254628A (en) | Agent for depressing consciousness level | |
| WO2020004182A1 (en) | Sleep-enhancing agent | |
| KR102597516B1 (en) | Fragrance composition for stress relief and psychological stability enhancement containing novel organic compounds as active ingredients | |
| JP5019016B2 (en) | Sleep improver and fragrance preparation | |
| JP5306159B2 (en) | Method for imparting mental enhancement effect in fragrance composition | |
| JPH01254629A (en) | Agent for raising consciousness level | |
| JP2003119491A (en) | Perfume composition for psychological exhilaranttion | |
| JPH11343497A (en) | Cosmetic | |
| JP2676543B2 (en) | Awareness lowering agent | |
| JPS63199293A (en) | Perfume composition and comsetics containing the same | |
| JP5306160B2 (en) | Use of a specific fragrance component for producing a fragrance composition for mental sedation, and a method for imparting a mental sedative effect in the fragrance composition | |
| WO2012176438A1 (en) | Sedative agent for vaporization and inhalation, and sedative perfume composition containing same | |
| JPH07305089A (en) | Conception promoter | |
| JP2007031347A (en) | Mental sedation composition | |
| JP4632895B2 (en) | Sleep improvement composition | |
| JPS63250315A (en) | Composition for promoting level of consciousness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040817 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040819 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070827 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080827 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080827 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090827 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100827 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100827 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110827 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120827 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130827 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |